Transforming growth factor-β (TGF-β) is a highly pleiotropic cytokine playing pivotal roles in immune regulation. TGF-β facilitates tumor cell survival and metastasis by targeting multiple cellular components. Focusing on its immunosuppressive functions, TGF-β antagonists have been employed for cancer treatment to enhance tumor immunity. TGF-β antagonists exert anti-tumor effects through #1 activating effector cells such as NK cells and cytotoxic 
INTRODUCTION
Transforming growth factor-β (TGF-β) superfamily consists of a large family of structurally related cytokines, which are classified into two main groups: TGF-β/Activin and bone morphogenetic proteins (BMPs) and growth/differentiation factors (GDFs) (1) . Among them, TGF-β has been well characterized as a representative potent immunosuppressive cytokine. TGF-β has been reported to inhibit immune system by modulating both effectors and suppressors. TGF-β directly inhibits innate immune cells such as macrophages and NK cells and adoptive immune cells such as CD4
＋ helper T cells and CD8 ＋ cytotoxic T cells, while expanding immunosuppressive regulatory T cells (Tregs) and inducing the recruitment of immunosuppressive myeloid-derived suppressor cells (2) . The immune surveillance system is one of the most important defense mechanisms against cancer progression. Attempts to enhance tumor immunity by various strategies have been tried as supportive anti-cancer therapies. The most potent immunosuppressive cytokine, TGF-β is massively produced and activated in tumor microenvironment, which allows invasive metastatic cancers to escape from immune surveillance (3). Thus, antagonizing TGF-β's functions has been implicated as the most potent anti-tumor immune therapy and some TGF-β antagonists have been on preclinical and clinical trials (4-6).
PROGNOSIS AND THE SIZE/NUMBER OF METASTASIS
Tumor recurrence by remote metastasis affects the prognosis of cancer patients after radical surgery. Cancer staging is evaluated by TNM classification, which describes the size and the extent of the Tumor, degree of the spread to regional lymph Nodes and the presence of Metastasis. TNM staging is widely employed as a global standard to plan the treatments and to indicate the prognosis (7) . Although there are no detailed parameters in metastasis defined in TNM staging, the size and the number of metastasis significantly affect the prognosis of the patients. In pulmonary metastasis from breast cancer, it has been reported that the size and the number of metastasis significantly correlate with prognosis and re-recurrence and the pulmonary metastasectomy is justified in case of small number of metastasis lesions (8) . It has been reported that an increase in tumor size and an increase in number of re-IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 4 August 2009 gional lymph nodes with metastasis were associated with diminution in cellular immunity (9) , which might be the consequence of the production of TGF-β by tumors themselves and tumor infiltrating immunosuppressive cells (10, 11) . Thus, one might expect that the number and the size of tumor and metastasis could be reduced by blocking TGF-β to achieve better prognosis.
TGF-β AND TUMOR IMMUNE SURVEILANCE-AFFECTING NUMBER OF METASTASIS
Although some tumors express tumor specific antigens, which can be recognized by immune system, tumor specific immune responses often fail to eradicate tumors because tumors evade immune surveillance by variety of strategies. Tumors themselves, tumor stromal cells and the myeloid-derived suppressor cells produce large amount of TGF-β, which is activated in the tumor microenvironment (12) (13) (14) . By its potent immunosuppressive effects, TGF-β strongly inhibits anti-tumor immunity.
Partly due to TGF-β, loss or down-regulation of MHC class I molecules is frequently observed in malignant cells, which makes them invisible to immune system (15) . Poorly immunogenic tumors with low expression of MHC class I can escape from attack by cytotoxic CD8
＋ T cells but they be- cell activity to reduce tumor metastasis number to some extent, although very highly activated NK cells are not significantly affected by anti-TGF-β antibody (19) . When TGF-β antagonists are administered systemically, untoward effects by autoimmune reactions might be possible (2). However, anti-TGF-β antibody increases cytotoxic T cell activity only locally at the tumor sites without activating systemic immune system, which indicates that the clinical application of TGF-β antagonists to cancer patients is tolerable (4) (5) (6) 19, 20) .
TGF-β AND TUMOR IMMUNE SUBVERSION-AFFECTING SIZE OF TUMOR AND METASTASIS
The balance between the effector cell populations and the suppressor cell populations finely tunes immune system. In malignant tumor environment, the suppressor populations such as Foxp3 over effector cell populations and suppress the effective anti-tumor immunity. Large amount of TGF-β produced and activated in tumor environment promotes the development and migration of these suppressor populations (21, 22) .
Recently, the novel subset of CD8 ＋ T cells is identified, which promotes growth of primary and metastatic tumor (23) . This CD8 ＋ T cell subset is distinct from the reported CD8 ＋ suppressor/regulatory T cells (24) . IL-17 is produced by this subset, which favors tumor growth by preventing tumor apoptosis. The same combination of cytokines to induce Th17 CD4 ＋ T cells in vitro, TGF-β and IL-6, subverts CD8 ＋ T cells into this IL-17 producing CD8 ＋ T cells (Fig. 2) .
The importance of IL-17 in inflammatory autoimmune disorders was first addressed by Nakae S et al. (25) and the CD4 ＋ T cell subset producing IL-17 was defined as Th17 by Stockinger B et al. (26) . Although T cells infiltrated in tumors produce IL-17 (27) , it has been controversial whether IL-17 promotes or inhibits tumor growth (28, 29) . Recently, it is reported that IL-17 produced by CD4 ＋ T cells, not CD8 ＋ T cells, promotes primary tumor growth through IL-6-Stat3 signaling pathway (30) . In poorly immunogenic 4T1 metastatic mammary tumor model, CD8
＋ T cell depletion decreases the primary tumor volume as well as metastasis size, indicating that some CD8 ＋ T cells (Fig. 3) . It is also to be de-termined whether TGF-β is involved in this effect. The IL-17/IL-23 axis might be the new mechanism of tumor immune subversion (33) .
PERSPECTIVE
Researchers used to focus on tumor immune surveillance by effector cell populations to enhance tumor immunity. Recent accumulation of data shows the importance of regulating tumor immune subversion by suppressor cell populations to reverse immune suppression against tumor. Antagonizing TGF-β successfully enhances tumor immune surveillance and reverses immune subversion, which results in the decrease in the number of metastasis and the size of tumor and metastasis. So far, TGF-β antagonists are applied to the treatment of terminal stage patients of certain highly malignant cancers only in clinical trials. By further confirmation of their efficacy and little toxicity, their application might be expanded to the patients with general cancers before the radical surgery to decrease the size of primary tumors and to prevent metastasis or to the patients before the metastasectomy to reduce the size and the number of metastasis.
